International study finds 1 in 8 patients have an infection following common procedures

A worldwide study which studied the incidence of surgical site infection (SSI) in over 12,000 patients who had gastro-intestinal surgery, across 66 countries has been published in The Lancet. The researchers quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. The findings of the prospective, international study included 1 in 8 patients experiencing infection post-operation for common procedures such as appendix removal.  In more than 20% of cases, patients developed infections which antibiotics should have protected them from

surgery-1822458_1920

Abstract 
Background Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries throughout the world.
Methods This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries
were stratified into high-income, middle-income, and low-income groups according to the UN’s Human Development Index (HDI).  The primary outcome measure was  the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models.

Findings Between Jan 4, 2016, and July 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries).
In total, 1538 (12·3%) patients  had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI.
The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries.

Interpretation Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance.

The full text article can be downloaded from The Lancet 

Advertisements

Infection outbreaks could be reduced by copper coated uniforms say University of Manchester scientists

Full reference :Sun, C. et al. |Durable and Washable Antibacterial Copper Nanoparticles Bridged by Surface Grafting Polymer Brushes on Cotton and Polymeric Materials| Journal of Nanomaterials|2018| DOI: 10.1155/2018/6546193
While the antibacterial properties of gold and silver are well known, and their effectiveness in reducing the growth of several microorganisms has been reported, the high cost of silver and gold has compelled material chemists to explore the possibility of using copper, as it has similar antimicrobial properties but is far less expensive. 

wire-2681887_1920Researchers from University of Manchester collaborated with Chinese scientists to create a ‘durable and washable, concrete like’ composite material made from antibacterial copper nanoparticles.  Rather than using the traditional process of copper coating the polymer brush technique (polymer surface grafting) to create a strong chemcial bond developed by team proved far more effective. They tested these nanoparticles on cotton and polyester as each material was brushed with the nanoparticles. The cotton and polyester coated-copper fabrics showed excellent antibacterial resistance against Staphylococcus aureus (S. aureus) and E. coli, even after being washed 30 times.

Abstract

To increase the durability of antibacterial coating on cotton and polymeric substrates, surface initiated grafting polymer brushes are introduced onto the substrates surface to bridge copper nanoparticles coatings and substrate. The morphologies of the composites consisting of the copper nanoparticles and polymer brushes were characterized with scanning electron microscopy (SEM).

It was found that copper nanoparticles were uniformly and firmly distributed on the surfaces of the substrates by the polymer brushes; meanwhile, the reinforced concrete-like structures were formed in the composite materials. The substrates coated by the copper nanoparticles showed the efficient antibacterial activity against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) even after washing by 30 cycles. The copper nanoparticles were tethered on the substrates by the strong chemical bonds, which led to the excellent washable fitness and durability. The change of the phase structure of the copper was analyzed to investigate the release mechanism of copper ions.

Full story at Science Daily

Related Infection Control Today Copper Coated Uniforms could Help Reduce Infection Transmission 

 

Soil sample analysis reveals new class of antibiotics

Scientists from Rockefeller University, New York have discovered a class of distinctive anitiboitics in environmental samples.  Tests show the compounds, called malacidins, annihilate several bacterial diseases that have become resistant to most existing antibiotics, including the superbug MRSA. As infectious diseases are the leading killer of humans worldwide, the team behind the discovery hope to be able to improve the drug’s effectiveness to exploit its full potential. 

dirty-2562268_1920

The researchers used a gene sequencing technique to analyse DNA extracted from more than 1,000 soil samples taken from across the US.  This led to the discovery of the malacidins, a distinctive class of antibiotics that are commonly encoded in soil microbiomes but have never been reported in culture-based natural products (NP)  discovery efforts.

The malacidins are active against multidrug-resistant pathogens, sterilize methicillinresistant Staphylococcus aureus skin infections in an animal wound model and did not select for resistance under laboratory conditions.

Full article at BBC News: New Antibiotic family discovered in dirt 

The full text article can be downloaded from Nature Microbiology

Full reference:  Hoover, B. M. | Culture- independent discovery of the  malacidins as
calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens | Nature Microbiology | 2018| Doi: https://doi.org/10.1038/s41564-018-0110-1

NICE will not update guidance on Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (2015) NICE guideline NG15

 NICE (National Institute for Health and Care Excellence)  check their guidelines regularly to ensure they remain up to date. They have decided not to update the guideline on antimicrobial stewardship at this time. NICE based the decision on surveillance 2 years after the publication of NICE’s guideline on antimicrobial stewardship (NICE guideline NG15) in 2015. 

Reason for the decision

Assessing the evidence

For this guideline,  NICE checked any policy or other guidance documents that had been issued or updated since NICE guideline NG15 was published. They also checked any Cochrane reviews related to the guideline – this included any updates to the 4 Cochrane reviews used to inform the recommendations during development of the guideline, as well as any new Cochrane reviews published since October 2014 when the original search took place.  In addition, NICE also  checked for any relevant National Institute for Health Research (NIHR) Signals. Each piece of evidence was checked against the guideline recommendations to assess any potential impact.

The policy, Cochrane reviews and NIHR Signals NICE examined did not indicate a need to update the guideline, therefore we did not undertake a formal evidence review. Furthermore, members of the original guideline committee were in agreement that there had been no substantial changes to the evidence base that would affect the guideline at this point .

NICE also checked for any relevant ongoing studies, and the impact of any publications arising from these in future will be monitored.

Overall decision 

 After considering the evidence described above as well as the views of topic experts and stakeholders, NICE  proposes  to not update this guideline.

See how NICE made the decision for further information

 

Progress report on the UK 5 year antimicrobial resistance strategy

The third annual progress report on the UK 5 year antimicrobial resistance (AMR) strategy, including future plans | Department of Health

pills-1173654_1920 (2)

The third annual progress report describes the activities and achievements in the third year of implementation of the UK 5 year antimicrobial resistance (AMR) strategy 2013 to 2018, including significant international achievements.

The UK AMR strategy represents an ambitious programme to slow the development and spread of AMR, taking a ‘One Health’ approach spanning people, animals, agriculture and the wider environment.

The report sets out progress made in 2016, and notes that for the remaining 2 years of the strategy, the programme will focus on delivery of the government’s ambitions set out in response to the review on AMR led by Lord O’Neill. These include ambitions to halve certain types of infection and the inappropriate use of antibiotics.

Full report: UK 5 Year Antimicrobial Resistance (AMR) Strategy 2013-2018. Annual progress report, 2016

 

Preventing infections and reducing AMR

This professional resource outlines the importance of infection prevention and control and how it can contribute to reducing antimicrobial resistance (AMR) | Public Health England

Every infection prevented reduces the need for and use of antimicrobials, which in turn lessens the potential for development of resistance. In the UK, the current rising threat from drug resistant organisms is from Gram-negative bacteria. Infections caused by Gram-negative organisms are increasing. This professional resource outlines the importance of infection prevention and control and how it can contribute to reducing antimicrobial resistance.

Full detail at Public Health England

online cover image
Image source: http://www.gov.uk

 

Vaccine update: October 2017

This vaccine update provides immunisation practitioners with the latest developments in vaccines, vaccination policies and procedures.

The vaccine update October edition 271 features:

  • influenza vaccination and patients on therapy for HIV infection (highly active anti-retroviral therapy – HAART)
  • survey for GPs about diagnosis and management of blood-borne viruses (BBV) among migrants
  • call for GP or school practice improvement
  • vaccine coverage for pertussis vaccination programme for pregnant women: update to June 2017
  • latest infant Meningitis B and school leaver MenACWY vaccine coverage estimates published
  • latest UK vaccine coverage figures for children aged up to 5 published
  • interpretation of vaccine storage requirements
  • The Vaccination of individuals with uncertain or incomplete vaccination status has been updated
  • flu vaccine information and availability for the children’s national flu vaccination programme 2017 to 2018
  • eligibility of children for flu vaccines
  • giving a second dose of LAIV
  • influenza Vaccines for the 2017 to 2018 influenza season
  • Hexavalent vaccine (Infanrix hexa®)
  • ordering for Infanrix hexa® (DTaP/IPV/Hib/HepB) is open on ImmForm
  • change to InterVax BCG vaccine ordering restrictions
  • to be aware of vaccine pack changes
  • change to Rotarix presentation
  • shortage of pneumococcal polysaccharide 23-valent vaccine (PPV23)
  • vaccine supply for non-routine programmes
  • historical vaccine development and introduction of routine vaccine programmes in the UK

Full update available at Public Health England